Patents by Inventor Wes Sisson

Wes Sisson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED ARGININE DEIMINASES
    Publication number: 20240084282
    Abstract: Provided are modified arginine deiminase (ADI) proteins, including ADI proteins that comprise one or more substitutions which increase expression in bacteria as insoluble and refoldable inclusion bodies. Also provided are methods of producing the modified ADI proteins, compositions comprising the ADI proteins, and related methods of treating arginine-dependent and related diseases such as cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 14, 2024
    Inventors: Richard E. Showalter, Robert J. Almassy, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang (Jason) Chen, Derek Lee
  • ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20220105160
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 7, 2022
    Inventors: Robert ALMASSY, Richard E. SHOWALTER, James A. THOMSON, Wes SISSON, Wei-Jong SHIA, Li-Chang CHEN, Yang LEE
  • Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
    Patent number: 11235037
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 1, 2022
    Assignee: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
    Patent number: 9789170
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 17, 2017
    Assignee: Polaris Group
    Inventors: Richard Showalter, Robert Almassy, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20160074487
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Application
    Filed: September 16, 2015
    Publication date: March 17, 2016
    Inventors: Richard Showalter, Robert Almassy, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • ARGINNE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT
    Publication number: 20140348814
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 27, 2014
    Applicant: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee